Induction and stability of human th17 cells require endogenous nos2 and cgmp-dependent no signaling

Journal of Experimental Medicine

Volumn 210, Issue 7, 2013, Pages 1433-1445

  Obermajer, Nataša ^a   Wong, Jeffrey L ^a   Edwards, Robert P ^a,b,c   Chen, Kong ^d   Scott, Melanie ^a   Khader, Shabaana ^d   Kolls, Jay K ^a,d   Odunsi, Kunle ^e   Billiar, Timothy R ^a   Kalinski, Pawel ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; RETINOID RELATED ORPHAN RECEPTOR GAMMA;

ANIMAL CELL; ARTICLE; CANCER CELL; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MOLECULAR STABILITY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TH1 CELL; TH17 CELL; TH2 CELL;

AGED; AGED, 80 AND OVER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84880653035     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20121277     Document Type: Article

References (87)

1. Acosta-Rodriguez, E.V., G. Napolitani, A. Lanzavecchia, and F. Sallusto. 2007a. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8:942-949. http://dx.doi.org/10.1038/ni1496
2. Acosta-Rodriguez, E.V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. Napolitani. 2007b. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639-646. http://dx.doi.org/10.1038/ni1467
3. Benchetrit, F., A. Ciree, V. Vives, G. Warnier, A. Gey, C. Sautès-Fridman, F. Fossiez, N. Haicheur, W.H. Fridman, and E. Tartour. 2002. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 99:2114-2121. http://dx.doi.org/10.1182/blood. V99.6.2114
4. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, H.L. Weiner, and V.K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441:235-238. http://dx.doi.org/10.1038/nature04753
5. Bettelli, E., M. Oukka, and V.K. Kuchroo. 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8:345-350. http://dx.doi.org/10.1038/ni0407-345
6. Bogdan, C. 1998. The multiplex function of nitric oxide in (auto)immunity. J. Exp. Med. 187:1361-1365. http://dx.doi.org/10.1084/jem.187.9.1361
7. Bogdan, C. 2001. Nitric oxide and the immune response. Nat. Immunol. 2:907-916. http://dx.doi.org/10.1038/ni1001-907
8. Bogdan, C. 2011. Regulation of lymphocytes by nitric oxide. Methods Mol. Biol. 677:375-393. http://dx.doi.org/10.1007/978-1-60761-869-0_24
9. Boniface, K., K.S. Bak-Jensen, Y. Li, W.M. Blumenschein, M.J. McGeachy, T.K. McClanahan, B.S. McKenzie, R.A. Kastelein, D.J. Cua, and R. de Waal Malefyt. 2009. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 206:535-548. http://dx.doi.org/10.1084/jem.20082293
10. Boughton-Smith, N.K., S.M. Evans, C.J. Hawkey, A.T. Cole, M. Balsitis, B.J. Whittle, and S. Moncada. 1993. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet. 342:338-340. http://dx.doi.org/10.1016/0140-6736(93)91476-3
11. Brahmachari, S., and K. Pahan. 2010. Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide. J. Immunol. 184:1799-1809. http://dx.doi.org/10.4049/jimmunol.0804394
12. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by l-arginine metabolism. Nat. Rev. Immunol. 5:641-654. http://dx.doi.org/10.1038/nri1668
13. Bronte, V., P. Serafini, A. Mazzoni, D.M. Segal, and P. Zanovello. 2003. l-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24:302-306. http://dx.doi.org/10.1016/S1471-4906 (03)00132-7
14. Chalmin, F., G. Mignot, M. Bruchard, A. Chevriaux, F. Végran, A. Hichami, S. Ladoire, V. Derangère, J. Vincent, D. Masson, et al. 2012. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity. 36:362-373. http://dx.doi.org/10.1016/j.immuni.2011.12.019
15. Charles, K.A., H. Kulbe, R. Soper, M. Escorcio-Correia, T. Lawrence, A. Schultheis, P. Chakravarty, R.G. Thompson, G. Kollias, J.F. Smyth, et al. 2009. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest. 119: 3011-3023. http://dx.doi.org/10.1172/JCI39065
16. Chizzolini, C., R. Chicheportiche, M. Alvarez, C. de Rham, P. Roux-Lombard, S. Ferrari-Lacraz, and J.M. Dayer. 2008. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood. 112:3696-3703. http://dx.doi.org/10.1182/blood-2008-05-155408
17. Chung, Y., S.H. Chang, G.J. Martinez, X.O. Yang, R. Nurieva, H.S. Kang, L. Ma, S.S. Watowich, A.M. Jetten, Q. Tian, and C. Dong. 2009. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 30:576-587. http://dx.doi.org/10.1016/j.immuni.2009.02.007
18. Coussens, L.M., and Z. Werb. 2002. Inflammation and cancer. Nature. 420:860-867. http://dx.doi.org/10.1038/nature01322
19. Coussens, L.M., L. Zitvogel, and A.K. Palucka. 2013. Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science. 339:286-291. http://dx.doi.org/10.1126/science.1232227
20. Culotta, E., and D.E. Koshland Jr. 1992. NO news is good news. Science. 258:1862-1865. http://dx.doi.org/10.1126/science.1361684
21. de Vera, M.E., R.A. Shapiro, A.K. Nussler, J.S. Mudgett, R.L. Simmons, S.M. Morris Jr., T.R. Billiar, and D.A. Geller. 1996. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc. Natl. Acad. Sci. USA. 93:1054-1059. http://dx.doi.org/10.1073/pnas.93.3.1054
22. Dolcetti, L., E. Peranzoni, S. Ugel, I. Marigo, A. Fernandez Gomez, C. Mesa, M. Geilich, G. Winkels, E. Traggiai, A. Casati, et al. 2010. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40:22-35. http://dx.doi.org/10.1002/eji.200939903
23. Fang, F.C. 2004. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat. Rev. Microbiol. 2:820-832. http://dx.doi.org/10.1038/nrmicro1004
24. Farrell, A.J., D.R. Blake, R.M. Palmer, and S. Moncada. 1992. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis. 51:1219-1222. http://dx.doi.org/10.1136/ard.51.11.1219
25. Feng, G., W. Gao, T.B. Strom, M. Oukka, R.S. Francis, K.J. Wood, and A. Bushell. 2008. Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur. J. Immunol. 38:2512-2527. http://dx.doi.org/10.1002/eji.200838411
26. Filipazzi, P., R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25:2546-2553. http://dx.doi.org/10.1200/JCO.2006.08.5829
27. Fischer, T.A., A. Palmetshofer, S. Gambaryan, E. Butt, C. Jassoy, U. Walter, S. Sopper, and S.M. Lohmann. 2001. Activation of cGMP-dependent protein kinase Ibeta inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells. J. Biol. Chem. 276:5967-5974. http://dx.doi.org/10.1074/jbc. M009781200
28. Gabrilovich, D.I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174. http://dx.doi.org/10.1038/nri2506
29. Geller, D.A., C.J. Lowenstein, R.A. Shapiro, A.K. Nussler, M. Di Silvio, S.C. Wang, D.K. Nakayama, R.L. Simmons, S.H. Snyder, and T.R. Billiar. 1993. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc. Natl. Acad. Sci. USA. 90:3491-3495. http://dx.doi.org/10.1073/pnas.90.8.3491
30. Ghoreschi, K., A. Laurence, X.P. Yang, C.M. Tato, M.J. McGeachy, J.E. Konkel, H.L. Ramos, L. Wei, T.S. Davidson, N. Bouladoux, et al. 2010. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature. 467:967-971. http://dx.doi.org/10.1038/nature09447
31. Gopal, R., Y. Lin, N. Obermajer, S. Slight, N. Nuthalapati, M. Ahmed, P. Kalinski, and S.A. Khader. 2012. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur. J. Immunol. 42:364-373. http://dx.doi.org/10.1002/eji.201141569
32. Grivennikov, S.I., F.R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell. 140:883-899. http://dx.doi.org/10.1016/j.cell.2010.01.025
33. Grivennikov, S.I., K. Wang, D. Mucida, C.A. Stewart, B. Schnabl, D. Jauch, K. Taniguchi, G.Y. Yu, C.H. Osterreicher, K.E. Hung, et al. 2012. Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 491:254-258.
34. Guo, L., G. Wei, J. Zhu, W. Liao, W.J. Leonard, K. Zhao, and W. Paul. 2009. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc. Natl. Acad. Sci. USA. 106:13463-13468. http://dx.doi.org/10.1073/pnas.0906988106
35. Hibbs, J.B. Jr., C. Westenfelder, R. Taintor, Z. Vavrin, C. Kablitz, R.L. Baranowski, J.H. Ward, R.L. Menlove, M.P. McMurry, J.P. Kushner, et al. 1992. Evidence for cytokine-inducible nitric oxide synthesis from l-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest. 89:867-877. http://dx.doi.org/10.1172/JCI115666
36. Hinrichs, C.S., A. Kaiser, C.M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z.A. Borman, P. Muranski, and N.P. Restifo. 2009. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 114:596-599. http://dx.doi.org/10.1182/blood-2009-02-203935
37. Hoechst, B., L.A. Ormandy, M. Ballmaier, F. Lehner, C. Krüger, M.P. Manns, T.F. Greten, and F. Korangy. 2008. A new population of myeloidderived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 135:234-243. http://dx.doi.org/10.1053/j.gastro.2008.03.020
38. Hooper, D.C., O. Bagasra, J.C. Marini, A. Zborek, S.T. Ohnishi, R. Kean, J.M. Champion, A.B. Sarker, L. Bobroski, J.L. Farber, et al. 1997. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. USA. 94:2528-2533. http://dx.doi.org/10.1073/pnas.94.6.2528
39. Huang, B., P.Y. Pan, Q. Li, A.I. Sato, D.E. Levy, J. Bromberg, C.M. Divino, and S.H. Chen. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123-1131. http://dx.doi.org/10.1158/0008-5472.CAN-05-1299
40. Hussain, S.P., L.J. Hofseth, and C.C. Harris. 2003. Radical causes of cancer. Nat. Rev. Cancer. 3:276-285. http://dx.doi.org/10.1038/nrc1046
41. Ivanov, I.I., B.S. McKenzie, L. Zhou, C.E. Tadokoro, A. Lepelley, J.J. Lafaille, D.J. Cua, and D.R. Littman. 2006. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 126:1121-1133. http://dx.doi.org/10.1016/j.cell.2006.07.035
42. Kalinski, P., and M. Moser. 2005. Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nat. Rev. Immunol. 5:251-260. http://dx.doi.org/10.1038/nri1569
43. Karpuzoglu, E., and S.A. Ahmed. 2006. Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: implications for immunity, autoimmune diseases, and apoptosis. Nitric Oxide. 15:177-186. http://dx.doi.org/10.1016/j.niox.2006.03.009
44. Kim, S.F., D.A. Huri, and S.H. Snyder. 2005. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science. 310:1966-1970. http://dx.doi.org/10.1126/science.1119407
45. Kolb, H., and V. Kolb-Bachofen. 1998. Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator? Immunol. Today. 19:556-561. http://dx.doi.org/10.1016/S0167-5699(98)01366-8
46. Kryczek, I., M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. Finlayson, D. Simeone, T.H. Welling, et al. 2009. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 114:1141-1149. http://dx.doi.org/10.1182/blood-2009-03-208249
47. Kusmartsev, S., Y. Nefedova, D. Yoder, and D.I. Gabrilovich. 2004. Antigenspecific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172:989-999.
48. Lança, T., and B. Silva-Santos. 2012. The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology. 1:717-725. http://dx.doi.org/10.4161/onci.20068
49. Lane, P., A. Traunecker, S. Hubele, S. Inui, A. Lanzavecchia, and D. Gray. 1992. Activated human T cells express a ligand for the human B cellassociated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur. J. Immunol. 22:2573-2578. http://dx.doi.org/10.1002/eji.1830221016
50. Langowski, J.L., X. Zhang, L. Wu, J.D. Mattson, T. Chen, K. Smith, B. Basham, T. McClanahan, R.A. Kastelein, and M. Oft. 2006. IL-23 promotes tumour incidence and growth. Nature. 442:461-465. http://dx.doi.org/10.1038/nature04808
51. Lee, S.W., H. Choi, S.Y. Eun, S. Fukuyama, and M. Croft. 2011. Nitric oxide modulates TGF-beta-directive signals to suppress Foxp3+ regulatory T cell differentiation and potentiate Th1 development. J. Immunol. 186:6972-6980. http://dx.doi.org/10.4049/jimmunol.1100485
52. Mahidhara, R.S., R.A. Hoffman, S. Huang, A. Wolf-Johnston, Y. Vodovotz, R.L. Simmons, and T.R. Billiar. 2003. Nitric oxide-mediated inhibition of caspase-dependent T lymphocyte proliferation. J. Leukoc. Biol. 74:403-411. http://dx.doi.org/10.1189/jlb.0602293
53. Mandruzzato, S., S. Solito, E. Falisi, S. Francescato, V. Chiarion-Sileni, S. Mocellin, A. Zanon, C.R. Rossi, D. Nitti, V. Bronte, and P. Zanovello. 2009. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182:6562-6568. http://dx.doi.org/10.4049/jimmunol.0803831
54. Mangan, P.R., L.E. Harrington, D.B. O'Quinn, W.S. Helms, D.C. Bullard, C.O. Elson, R.D. Hatton, S.M. Wahl, T.R. Schoeb, and C.T. Weaver. 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 441:231-234. http://dx.doi.org/10.1038/nature04754
55. Mantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related inflammation. Nature. 454:436-444. http://dx.doi.org/10.1038/nature07205
56. Martin-Orozco, N., and C. Dong. 2009. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr. Opin. Investig. Drugs. 10:543-549.
57. Martin-Orozco, N., P. Muranski, Y. Chung, X.O. Yang, T. Yamazaki, S. Lu, P. Hwu, N.P. Restifo, W.W. Overwijk, and C. Dong. 2009. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 31:787-798. http://dx.doi.org/10.1016/j.immuni.2009.09.014
58. Mazzoni, A., V. Bronte, A. Visintin, J.H. Spitzer, E. Apolloni, P. Serafini, P. Zanovello, and D.M. Segal. 2002. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168:689-695.
59. McCartney-Francis, N., J.B. Allen, D.E. Mizel, J.E. Albina, Q.W. Xie, C.F. Nathan, and S.M. Wahl. 1993. Suppression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. 178:749-754. http://dx.doi.org/10.1084/jem.178.2.749
60. Miljkovic, D., and V. Trajkovic. 2004. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev. 15:21-32. http://dx.doi.org/10.1016/j.cytogfr.2003.10.003
61. Miyahara, Y., K. Odunsi, W. Chen, G. Peng, J. Matsuzaki, and R.F. Wang. 2008. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. USA. 105:15505-15510. http://dx.doi.org/10.1073/pnas.0710686105
62. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J.A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 111: 4233-4244. http://dx.doi.org/10.1182/blood-2007-07-099226
63. Muranski, P., A. Boni, P.A. Antony, L. Cassard, K.R. Irvine, A. Kaiser, C.M. Paulos, D.C. Palmer, C.E. Touloukian, K. Ptak, et al. 2008. Tumorspecific Th17-polarized cells eradicate large established melanoma. Blood. 112:362-373. http://dx.doi.org/10.1182/blood-2007-11-120998
64. Nagaraj, S., and D.I. Gabrilovich. 2010. Myeloid-derived suppressor cells in human cancer. Cancer J. 16:348-353. http://dx.doi.org/10.1097/PPO.0b013e3181eb3358
65. Nagy, G., A. Koncz, and A. Perl. 2003. T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+-and redox-dependent production of nitric oxide. J. Immunol. 171:5188-5197.
66. Niedbala, W., X.Q. Wei, C. Campbell, D. Thomson, M. Komai-Koma, and F.Y. Liew. 2002. Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMP. Proc. Natl. Acad. Sci. USA. 99:16186-16191. http://dx.doi.org/10.1073/pnas.252464599
67. Niedbala, W., J.C. Alves-Filho, S.Y. Fukada, S.M. Vieira, A. Mitani, F. Sonego, A. Mirchandani, D.C. Nascimento, F.Q. Cunha, and F.Y. Liew. 2011. Regulation of type 17 helper T-cell function by nitric oxide during inflammation. Proc. Natl. Acad. Sci. USA. 108:9220-9225. http://dx.doi.org/10.1073/pnas.1100667108
68. Numasaki, M., J. Fukushi, M. Ono, S.K. Narula, P.J. Zavodny, T. Kudo, P.D. Robbins, H. Tahara, and M.T. Lotze. 2003. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 101:2620-2627. http://dx.doi.org/10.1182/blood-2002-05-1461
69. Obermajer, N., R. Muthuswamy, J. Lesnock, R.P. Edwards, and P. Kalinski. 2011. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 118:5498-5505. http://dx.doi.org/10.1182/blood-2011-07-365825
70. Ochoa, J.B., B. Curti, A.B. Peitzman, R.L. Simmons, T.R. Billiar, R. Hoffman, R. Rault, D.L. Longo, W.J. Urba, and A.C. Ochoa. 1992. Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J. Natl. Cancer Inst. 84:864-867. http://dx.doi.org/10.1093/jnci/84.11.864
71. Rodriguez, P.C., M.S. Ernstoff, C. Hernandez, M. Atkins, J. Zabaleta, R. Sierra, and A.C. Ochoa. 2009. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69:1553-1560. http://dx.doi.org/10.1158/0008-5472. CAN-08-1921
72. Schneemann, M., and G. Schoeden. 2007. Macrophage biology and immunology: man is not a mouse. J. Leukoc. Biol. 81:579, discussion :580. http://dx.doi.org/10.1189/jlb.1106702
73. Schneemann, M., and G. Schoedon. 2002. Species differences in macrophage NO production are important. Nat. Immunol. 3:102. http://dx.doi.org/10.1038/ni0202-102a
74. Serafini, P., K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello. 2006. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203:2691-2702. http://dx.doi.org/10.1084/jem.20061104
75. Stritesky, G.L., N. Yeh, and M.H. Kaplan. 2008. IL-23 promotes maintenance but not commitment to the Th17 lineage. J. Immunol. 181:5948-5955.
76. Thomas, D.D., M.G. Espey, L.A. Ridnour, L.J. Hofseth, D. Mancardi, C.C. Harris, and D.A. Wink. 2004. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc. Natl. Acad. Sci. USA. 101:8894-8899. http://dx.doi.org/10.1073/pnas.0400453101
77. van Beelen, A.J., Z. Zelinkova, E.W. Taanman-Kueter, F.J. Muller, D.W. Hommes, S.A. Zaat, M.L. Kapsenberg, and E.C. de Jong. 2007. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity. 27:660-669. http://dx.doi.org/10.1016/j.immuni.2007.08.013
78. Veldhoen, M., R.J. Hocking, C.J. Atkins, R.M. Locksley, and B. Stockinger. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24: 179-189. http://dx.doi.org/10.1016/j.immuni.2006.01.001
79. Vuk-Pavlovic, S., P.A. Bulur, Y. Lin, R. Qin, C.L. Szumlanski, X. Zhao, and A.B. Dietz. 2010. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate. 70:443-455.
80. Wang, L., T. Yi, M. Kortylewski, D.M. Pardoll, D. Zeng, and H. Yu. 2009. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206:1457-1464. http://dx.doi.org/10.1084/jem.20090207
81. Weinberg, J.B., D.L. Granger, D.S. Pisetsky, M.F. Seldin, M.A. Misukonis, S.N. Mason, A.M. Pippen, P. Ruiz, E.R. Wood, and G.S. Gilkeson. 1994. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J. Exp. Med. 179:651-660. http://dx.doi.org/10.1084/jem.179.2.651
82. Wilke, C.M., K. Bishop, D. Fox, and W. Zou. 2011. Deciphering the role of Th17 cells in human disease. Trends Immunol. 32:603-611. http://dx.doi.org/10.1016/j.it.2011.08.003
83. Wilson, N.J., K. Boniface, J.R. Chan, B.S. McKenzie, W.M. Blumenschein, J.D. Mattson, B. Basham, K. Smith, T. Chen, F. Morel, et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8:950-957. http://dx.doi.org/10.1038/ni1497
84. Wu, S.G., K.J. Rhee, E. Albesiano, S. Rabizadeh, X.Q. Wu, H.R. Yen, D.L. Huso, F.L. Brancati, E. Wick, F. McAllister, et al. 2009. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15:1016-1022. http://dx.doi.org/10.1038/nm.2015
85. Zea, A.H., P.C. Rodriguez, M.B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, et al. 2005. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65:3044-3048.
86. Zhou, L., I.I. Ivanov, R. Spolski, R. Min, K. Shenderov, T. Egawa, D.E. Levy, W.J. Leonard, and D.R. Littman. 2007. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967-974. http://dx.doi.org/10.1038/ni1488
87. Zou, W., and N.P. Restifo. 2010. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10:248-256. http://dx.doi.org/10.1038/nri274